Details for Patent: 8,487,129
✉ Email this page to a colleague
Which drugs does patent 8,487,129 protect, and when does it expire?
Patent 8,487,129 protects PYLARIFY and is included in one NDA.
This patent has thirty-four patent family members in sixteen countries.
Summary for Patent: 8,487,129
Title: | Heterodimers of glutamic acid |
Abstract: | Compounds of Formula (Ia) ##STR00001## wherein R is a C.sub.6-C.sub.12 substituted or unsubstituted aryl, a C.sub.6-C.sub.12 substituted or unsubstituted heteroaryl, a C.sub.1-C.sub.6 substituted or unsubstituted alkyl or --NR'R', Q is C(O), O, NR', S, S(O).sub.2, C(O).sub.2 (CH2)p Y is C(O), O, NR', S, S(O).sub.2, C(O).sub.2 (CH2)p Z is H or C.sub.1-C.sub.4 alkyl, R' is H, C(O), S(O).sub.2, C(O).sub.2, a C.sub.6-C.sub.12 substituted or unsubstituted aryl, a C.sub.6-C.sub.12 substituted or unsubstituted heteroaryl or a C.sub.1-C.sub.6 substituted or unsubstituted alkyl, when substituted, aryl, heteroaryl and alkyl are substituted with halogen, C.sub.6-C.sub.12 heteroaryl, --NR'R' or COOZ, which have diagnostic and therapeutic properties, such as the treatment and management of prostate cancer and other diseases related to NAALADase inhibition. Radiolabels can be incorporated into the structure through a variety of prosthetic groups attached at the X amino acid side chain via a carbon or hetero atom linkage. |
Inventor(s): | Babich; John W. (Cambridge, MA), Zimmerman; Craig N. (Cambridge, MA), Maresca; Kevin P. (Cambridge, MA) |
Assignee: | Molecular Insight Pharmaceuticals, Inc. (Cambridge, MA) |
Application Number: | 13/294,677 |
Patent Claim Types: see list of patent claims | Compound; |
Drugs Protected by US Patent 8,487,129
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Progenics Pharms Inc | PYLARIFY | piflufolastat f-18 | SOLUTION;INTRAVENOUS | 214793-001 | May 26, 2021 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | Y | ⤷ Try a Trial | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 8,487,129
Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
---|---|---|---|---|---|
Australia | 2007316391 | ⤷ Try a Trial | |||
Brazil | PI0718700 | ⤷ Try a Trial | |||
Canada | 2669127 | ⤷ Try a Trial | |||
China | 101778910 | ⤷ Try a Trial | |||
China | 103922998 | ⤷ Try a Trial | |||
Cyprus | 1116610 | ⤷ Try a Trial | |||
Denmark | 2097111 | ⤷ Try a Trial | |||
>Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |